Thank you, Madam Chair.
My first set of questions is for Dr. Michaud of BioCanRx.
The Liberal government recently announced a series of cuts to science funding. It's affecting over a dozen science organizations. One of them is BioCanRx.
Can you walk the committee through how some of these recently announced funding reductions will impact BioCanRx's current research portfolio and future research ambitions, particularly those around cancer immunotherapy projects?